Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 7, 2007, Pages 813-821

  Hawkey, C J ^a   Jones, R H ^b   Yeomans, N D ^c   Scheiman, J M ^d   Talley, N J ^e   Goldstein, J L ^f   Ahlbom, H ^g   Naesdal J ^g  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RANITIDINE;

ABDOMINAL PAIN; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LONG TERM CARE; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; STOMACH ULCER; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; OMEPRAZOLE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33947195984     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03210.x     Document Type: Article

References (29)

1. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 105: 3S-9S.
2. Cullen DJ, Seager JM, Holmes S, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000; 14: 177-85.
3. Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6-13.
4. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27: 1668-73.
5. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res 2001; 18: 1367-72.
6. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32 (3 Suppl. 1): 25-32.
7. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33.
8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 282: 1247-55.
9. Lisse JE, Perlman M, Johannson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib vs. naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Inter Med 2003; 139: 539-46.
10. Veldhuyzen van Zanten SJO, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005; 19: 285-303.
11. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 25 (Suppl. 51): 8-16.
12. Elliot SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432-4.
13. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Clin Gastroenterol 2001; 15: 755-73.
14. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal antiinflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753-8.
15. Yeomans N, Wilson I, Langstrom G, et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328-34.
16. Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028-36.
17. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10.
18. Goldstein JL, Johansen JF, Suchower LJ, Brown KA. Healing of gastric ulcers with esomeprazole vs. ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650-7.
19. Junghard O, Lauritsen K, Talley NJ, et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg Suppl 1998; 583: 106-11.
20. Junghard O, Wiklund I. Validation of a 4-graded scale for severity of heartburn in symptomatic GERD patients [abstract]. Gut 2004; 53 (Suppl. VI): A103.
21. Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207-23.
22. Tenenbaum J. The epidemiology of non-steroidal anti-inflammatory drugs. Can J Gastroenterol 1999; 13: 119-22.
23. Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004; 126: 660-4.
24. Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823-57.
25. Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Semin Arthritis Rheum 2000; 30: 167-79.
26. Levine RA, Schwartzel EH. Effect of indomethacin on basal and histamine-stimulated human gastric acid secretion. Gut 1984; 25: 718-22.
27. Savarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998; 43: 459-63.
28. Kulkarni SG, Parikh SS, Shankhpal PD, et al. Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Am J Gastroenterol 1999; 94: 382-6.
29. Bouras EP, Burton DD, Camilleri M, Stephens DA, Thomforde GM. Effect of cyclooxygenase inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterol Motil 2004; 16: 729-35.